Arrowhead Completed Enrollment in Phase 3 YOSEMITE Trial of Zodasiran for HoFH

-Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasir...

July 29, 2026 | Wednesday | News
Sanofi Discontinues Development of Amlitelimab for Atopic Dermatitis

Sanofi announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis ...

July 28, 2026 | Tuesday | News
Fresenius Launches €200 Million Venture Fund to Invest in Healthcare Innovation

The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...

July 27, 2026 | Monday | News
Bio-Thera Solutions Initiates Phase I Trial of CD25-Targeting ADC BAT8013 in Advanced Solid Tumors

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...

July 27, 2026 | Monday | News
Synaptiq Therapeutics Launches to Advance SYN-001 for 22q11DS Neuropsychiatric Symptoms

A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...

July 27, 2026 | Monday | News
ArkBio Completes Healthy Volunteer Dosing in Phase I Trial of Long-Acting Influenza Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK...

July 27, 2026 | Monday | News
Arcus Biosciences and AVEO Partner to Evaluate Casdatifan Plus Tivozanib in Kidney Cancer Study

  This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib a...

July 24, 2026 | Friday | News
Halozyme Partners with Incyte to Develop Subcutaneous mutCALR Therapy Using ENHANZE

  Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to...

July 22, 2026 | Wednesday | News
Argo Biopharma Doses First Participant in Phase I Trial of BW-41012

BW-41012 represents the eighth clinical candidate from Argo's innovative RNAi pipeline, and is being evaluated for the prevention of thromboembolic disea...

July 21, 2026 | Tuesday | News
Lupin Spins Out Oncology Programs into Kaveri Therapeutics to Advance Global Clinical Development

  Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)  Global pharmaceutical leader Lupin Limited &n...

July 22, 2026 | Wednesday | News
Samsung Biologics Announced CHF 1.46 Billion Tender Offer to Acquire PolyPeptide

  Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding ...

July 21, 2026 | Tuesday | News
Bayer and Henry Ford Health Partner to Expand Patient Access to Clinical Trials

Bayer, a global life sciences company, and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The w...

July 20, 2026 | Monday | News
Dana-Farber, OSUCCC–James and IBCRF Launch Collaborative Research Initiative for Metastatic Inflammatory Breast Cancer

In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...

July 20, 2026 | Monday | News
Parse Biosciences Expands Single Cell Sequencing Access in Asia-Pacific Through Garvan Institute Partnership

Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Fa...

July 20, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close